349 related articles for article (PubMed ID: 12860497)
41. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
42. Galantamine treatment in outpatients with mild Alzheimer's disease.
Richarz U; Gaudig M; Rettig K; Schauble B
Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
[TBL] [Abstract][Full Text] [Related]
43. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
44. Galantamine: use in Alzheimer's disease and related disorders.
Bullock R
Expert Rev Neurother; 2004 Mar; 4(2):153-63. PubMed ID: 15853556
[TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
46. Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.
Senanarong V; Poungvarin N; Phanthumchinda K; Thavichachart N; Chankrachang S; Praditsuwan R; Nidhinandana S
J Med Assoc Thai; 2009 Mar; 92 Suppl 2():S12-8. PubMed ID: 19562980
[TBL] [Abstract][Full Text] [Related]
47. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
48. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
49. Non-cognitive benefits of galantamine (Reminyl) treatment in vascular dementia.
Kurz A
Acta Neurol Scand Suppl; 2002; 178():19-24. PubMed ID: 12492788
[TBL] [Abstract][Full Text] [Related]
50. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Rockwood K; Howlett SE; Hoffman D; Schindler R; Mitnitski A
Alzheimers Dement; 2017 Oct; 13(10):1098-1106. PubMed ID: 28341540
[TBL] [Abstract][Full Text] [Related]
51. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
53. Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.
Tangwongchai S; Thavichachart N; Senanarong V; Poungvarin N; Phanthumchinda K; Praditsuwan R; Nidhinandana S; Chankrachang S
Am J Alzheimers Dis Other Demen; 2008 Dec-2009 Jan; 23(6):593-601. PubMed ID: 18845693
[TBL] [Abstract][Full Text] [Related]
54. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
Tariot PN
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
[TBL] [Abstract][Full Text] [Related]
55. Treatment options: the latest evidence with galantamine (Reminyl).
Erkinjuntti T
J Neurol Sci; 2002 Nov; 203-204():125-30. PubMed ID: 12417370
[TBL] [Abstract][Full Text] [Related]
56. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
57. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
58. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.
Galasko D; Kershaw PR; Schneider L; Zhu Y; Tariot PN
J Am Geriatr Soc; 2004 Jul; 52(7):1070-6. PubMed ID: 15209643
[TBL] [Abstract][Full Text] [Related]
59. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.
Wilkinson D; Murray J
Int J Geriatr Psychiatry; 2001 Sep; 16(9):852-7. PubMed ID: 11571763
[TBL] [Abstract][Full Text] [Related]
60. Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer's disease with cerebrovascular disease.
Karamacoska D; Chan DKY; Leung I; Liu JX; Brodaty H; Fahey PP; Bensoussan A; Chang DH
PLoS One; 2023; 18(3):e0265285. PubMed ID: 36920949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
